Gilead Sciences’ liver disease portfolio delivered surprisingly robust performance in the second quarter, jumping 17% as the company awaits next week’s potential FDA approval of seladelpar in primary biliary cholangitis.
In the latest setback for the pharma industry and its allies, the United States District Court for the Southern District of Ohio dismissed a U.S. Chamber of Commerce lawsuit on the grounds of improper venue.
MedAdNews spoke with Andrew Bast, chief strategy officer of Greater Than One, about the critical importance of health literacy for patients, brands, and marketers.
Data-driven strategies for lifesciences commercialization
Developers of vapes for migraine, asthma will need to win over sceptics
To successfully influence prescribing among HCPs, we need a better understanding of what lies at the center.